Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Tuesday, November 10, 2009, 10:09AM ET - U.S. Markets close in 5 hours and 51 minutes. Dow Up 0.11% Nasdaq Up 0.16%
SciClone Pharmaceuticals, Inc. (SCLN)At 9:53AM ET: 2.93  Up 0.06 (2.09%)  
MORE ON SCLN
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
SciClone Pharmaceuticals, Inc.
950 Tower Lane
Suite 900
Foster City, CA 94404-2125
United States - Map
Phone: 650-358-3456
Fax: 650-358-3469
Web Site: http://www.sciclone.com

DETAILS 
Index Membership:N/A
Sector:Healthcare
Industry:Drug Manufacturers - Other
Full Time Employees:227

BUSINESS SUMMARY 
SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally. It provides ZADAXIN for the treatment of hepatitis B and hepatitis C, and certain cancers, as well as for use as a vaccine adjuvant. The company’s products under development includes ZADAXIN, a thymalfasin, which is in Phase III clinical trials for the treatment of stage IV melanoma; RP101, which is in Phase II clinical trials for the treatment of pancreatic cancer; and SCV-07, which is in Phase II clinical trials for the treatment of hepatitis C virus and oral mucositis. It also holds Chinese marketing rights from Biocompatibles International plc. for DC Bead, a product for the treatment of liver cancer or hepatocellular carcinoma. The company was founded in 1989 and is headquartered in Foster City, California.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on SciClone Pharmaceuticals, Inc.


    CORPORATE GOVERNANCE 
    SciClone Pharmaceuticals, Inc.'s Corporate Governance Quotient (CGQ®) as of 6-Nov-09 is better than 84.7% of Russell 3000 companies and 88.2% of Pharmaceuticals, Biotechnology & Life Sciences companies.
    Brought to you by Institutional Shareholder Services.

    KEY EXECUTIVES 
     PayExercised
    Dr. Friedhelm Blobel Ph.D.,
    Chief Exec. Officer and Pres
    $ 881.00K $ 0
    Mr. Gary S. Titus C.P.A., 49
    Chief Financial Officer and Sr. VP of Fin.
    $ 42.00K $ 0
    Mr. Hans P. Schmid , 57
    Pres of SciClone Pharmaceuticals International Ltd and Managing Director of SciClone Pharmaceuticals International Ltd
    $ 458.00K $ 0
    Mr. Ivan B. Hui , 46
    Principal Accounting Officer and Assistant VP of Fin.
    $ 253.00K $ 0
    Dr. Israel Rios M.D., 62
    Chief Medical Officer and Sr. VP of Medical Affairs
    $ 416.00K $ 0
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis